
|Articles|August 19, 2014
- Immunotherapy (Issue 3)
- Volume 3
- Issue 1
The Management of Side Effects Associated With Immunotherapies
Author(s)Jedd D. Wolchok, MD, PhD
Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the management of side effects associated with immunotherapies.
Advertisement
Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the management of side effects associated with immunotherapies.
View more about managing side effects and the limitations of immunotherapies > >
Articles in this issue
over 11 years ago
A Brief History of Immunotherapyover 11 years ago
Better Biomarker Testing Needed in Immuno-Oncologyover 11 years ago
Autoimmunity and Limitations of Cancer Vaccinesover 11 years ago
The Next Wave in Immunotherapy: Combinationsover 11 years ago
Future Immune Checkpoint StrategiesAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































